SCHEMBL2384404

SCHEMBL2384404

CC(=O)NNc1ccc(Cl)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.63
ALOX5 P09917 1/20 0.63
TSHR P16473 1/20 0.63
PTGS2 P35354 6/20 0.62
GAA P10253 8/20 0.54
ALDH1A1 P00352 7/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
TDP1 Q9NUW8 2/20 0.54
ALOX12 P18054 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C19 P33261 1/20 0.53
RAB9A P51151 1/20 0.53
LMNA P02545 4/20 0.53
AGTR1 P30556 2/20 0.53
NPC1 O15118 1/20 0.53
POLB P06746 1/20 0.53
EPHX1 P07099 1/20 0.52
IDO1 P14902 1/20 0.51
MAPT P10636 2/20 0.51
MAPK1 P28482 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10942888 0.82 CYP3A4 (0.68) CYP3A4ALOX5TSHRPTGS2GAA
SCHEMBL9461862 0.82 PTGS2 (0.67) CYP3A4PTGS2GAAALDH1A1SMN1; SMN2
SCHEMBL28045428 0.82 PTGS2 (0.67) CYP3A4PTGS2GAAALDH1A1SMN1; SMN2
SCHEMBL15541389 0.80 PTGS2 (0.64) CYP3A4PTGS2GAAALDH1A1SMN1; SMN2
SCHEMBL8743016 0.80 KMT2A (0.68) CYP3A4ALOX5TSHRGAAALDH1A1
SCHEMBL424604 0.80 CYP3A4 (0.65) CYP3A4ALOX5TSHRPTGS2GAA
SCHEMBL6599028 0.79 CYP3A4 (0.59) CYP3A4ALOX5TSHRGAAALDH1A1
SCHEMBL2237027 0.79 PTGS2 (0.58) CYP3A4PTGS2GAAALDH1A1SMN1; SMN2
SCHEMBL8602491 0.78 NPC1 (0.63) CYP3A4PTGS2GAAALDH1A1SMN1; SMN2
SCHEMBL425708 0.78 GAA (0.63) CYP3A4ALOX5TSHRGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115894326-B 2, 3-Hydrogen substituted aminoindole derivative, preparation method and application thereof 佛山大学 2025-02-11 CN disclosed
CN-115894326-A 2,3-hydrogen substituted aminoindole derivative, preparation method and application thereof 佛山科学技术学院 2023-04-04 CN disclosed
CN-109467528-B Synthesis method of 1-aminoindole derivative 佛山科学技术学院 2020-11-06 CN disclosed
WO-2016092559-A1 SUBSTITUTED PYRAZOLE DERIVATIVES HAVING ACTIVITY AS FUNGICIDES OAT & IIL INDIA LABORATORIES PRIVATE LIMITED (IN) 2016-06-16 WO disclosed
CN-104945403-A Tetrahydrobenzo [ e ] [1,2,4] triaza compounds and preparation method thereof UNIV DALIAN TECH 2015-09-30 CN disclosed
US-8012991-B2 3-(2,4-dimethoxyphenyl)-1,9-dimethyl-2-oxo-2,9-dihydro-1H-pyrido[2,3-b]indole-6-carboxylic acid; gamma-aminobutyric acid modulator; anticarcinogenic, antitumor, antiproliferative agent; amidating a 2-aminoindole with an alpha-substituted-beta-hydroxy-alkyl acrylate SANOFI-AVENTIS (FR) 2011-09-06 US disclosed
US-20080214538-A1 Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics SANOFI-AVENTIS (FR) 2008-09-04 US disclosed
US-7390818-B2 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-06-24 US disclosed
EP-1556382-B1 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2008-05-28 EP disclosed
US-20050288318-A1 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2005-12-29 US disclosed
EP-1556382-A1 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2005-07-27 EP disclosed
WO-2004041817-A1 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288318-A1 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics PNPO, PDXK, PLPBP CYP3A4 218/4885ALOX5 353/4885TSHR 713/4885
US-20080214538-A1 Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics PNPO, PLPBP, DPYD CYP3A4 296/4885ALOX5 517/4885TSHR 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.